NEW YORK – Israeli infectious disease diagnostics firm MeMed is ramping up commercialization efforts for its MeMed BV diagnostic test and its point-of-care MeMed Key testing platform.
The company said this week that the test and platform received CE-IVD marks, allowing it to begin placing them in health centers across the EU. Additionally, MeMed is in the middle of a clinical study in the US that will support a Food and Drug Administration submission and US launch sometime next year.